logo
Share SHARE
FONT-SIZE Plus   Neg

Pfizer's Rheumatoid Arthritis Drug Xeljanz Gets Approval In Japan

Pharmaceutical giant Pfizer Inc. (PFE) Monday said the Japanese Ministry of Health, Labor and Welfare has approved Xeljanz for the treatment of adults with rheumatoid arthritis or RA who have had an inadequate response to existing therapies. The company added saying the drug may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying antirheumatic drug, such as methotrexate.

Xeljanz is expected to be initially made available in Japan to medical institutions participating in an all-patient surveillance program. The drug will be commercially available in Japan after the National Health Insurance listing and will be co-promoted in Japan by Pfizer and Takeda Pharmaceutical Company Limited.

The approval of Xeljanz in Japan is supported by a multi-study, global clinical development program, which evaluated the drug in approximately 5,000 patients across various RA patient populations.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Crypto Co., engaged in the digital currencies and blockchain sector, announced its plans to execute a 10-for-1 stock split, citing the significant growth in the value and demand for its shares amid the ongoing digital currency market boost. CEO Mike Poutre said, ""We are aware of the recent fluctuation in our stock, and want to see orderly market activity surrounding the trading of our stock." Teva Pharmaceutical Industries Ltd. (TEVA) said Thursday that it plans to reduce 14,000 jobs globally or more than 25% of its total workforce in the next two years. It will immediately suspend dividends on ordinary shares, and cancel bonus for 2017. The company will continue to review the potential for additional divestment of non-core assets. Checkout the few notable companies that are scheduled to release quarterly financial results on Thursday, December 14, 2017. - Growing Cloud Footprint To Bolster ADBE Q4 - COST Q1 Likely To Benefit From Holiday Weekend Sales - Growth And Diversification Strategy To Boost JBL Q1 Results - Will Cloud Propel ORCL Quarterly Performance?
comments powered by Disqus
Follow RTT